The Food and Drug Administration is warning consumers not to use off-brand weight loss drugs containing semaglutide, the active ingredient in Ozempic and Wegovy.
Semaglutide, meant for patients with type 2 diabetes, is a glucagon-like peptide-1 receptor agonist, meaning that it mimics the GLP-1 hormone released in the GI tract to signal fullness, helping people shed excess weight.
“Patients and health care professionals should understand that the agency does not review compounded versions of these drugs for safety, effectiveness, or quality,” the FDA wrote.“Products containing these salts, such as semaglutide sodium and semaglutide acetate, have not been shown to be safe and effective,” the agency added.
Compounded drugs are not FDA-approved, officials said, which means they have not been vetted for safety in humans.“Patients should not use a compounded drug if an approved drug is available to treat a patient,” the FDA wrote. “Patients and health care professionals should understand that the agency does not review compounded versions of these drugs for safety, effectiveness, or quality.”
But if there is a shortage of a particular drug, a compounded version could be produced if it meets certain FDA requirements.“Patients should only obtain drugs containing semaglutide with a prescription from a licensed health care provider, and only obtain medicines from state-licensed pharmacies or outsourcing facilities registered with FDA,” officials said.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
FDA warns consumers not to use off-brand versions of Ozempic, WegovyConsumers should only use semaglutide prescribed by a health care provider and filled by a licensed pharmacy, FDA said.
Lire la suite »
FDA warns consumers not to use off-brand versions of Ozempic, WegovySales of semaglutide products have soared in the past few years after the drug was shown to spur fast and significant weight loss.
Lire la suite »
FDA warns consumers not to use off-brand versions of Ozempic, WegovyThe U.S. Food and Drug Administration is warning consumers not to use versions of the popular weight-loss drug used in Ozempic and Wegovy and sold online because they might not contain the same ingredients as prescription products and may not be safe or effective.
Lire la suite »
FDA warns consumers not to use off-brand versions of Ozempic, WegovyThe U.S. Food and Drug Administration is warning consumers not to use versions of the popular weight-loss drug used in Ozempic and Wegovy and sold online because they might not contain the same ingredients as prescription products and may not be safe or effective. Agency officials said this week that they have received reports of problems after patients used versions of semaglutide, the active ingredient in the brand-name medications, which have been compounded or mixed in pharmacies. Consumers should only use semaglutide prescribed by a health are provider and filled by a licensed pharmacy, FDA said.
Lire la suite »
Ozempic Craze Has Spawned a Sketchy Black Market, FDA WarnsThe FDA has received adverse event reports from people using compounded semaglutide, which might not contain the same version of the popular obesity drug.
Lire la suite »
As some turn to compounded version of Ozempic for weight loss, FDA issues warningThe U.S. Food and Drug Administration weighed in on the matter, warning that it has received 'adverse event reports' after patients used compounded semaglutide — the active ingredient in Ozempic and Wegovy.
Lire la suite »